{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:35:49Z","timestamp":1790933749572,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p>Many patients with chronic lymphocytic leukemia (CLL) develop progressive treatment\u2010resistant disease. Rituximab (RTX), a monoclonal antibody targeting CD20 on B lymphocytes and widely used in other indolent B\u2010cell neoplasms is less efficacious in CLL, possibly because of associated complement deficiencies. Initial <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> observations support the central role of complement in rituximab\u2010mediated loss of CD20<jats:sup>+<\/jats:sup> cells in CLL. In an open trial conducted in outpatient hematology clinics in Israel and Greece, we examined whether providing complement by concurrent administration of fresh frozen plasma (FFP) would enhance the effect of RTX in CLL. Five patients with severe treatment\u2010resistant CLL were included in the trial. All had been previously treated with fludarabine, and three also failed treatment with RTX. Each patient was treated with two units of FFP followed with RTX 375 mg\/m<jats:sup>2<\/jats:sup> as a single agent, repeated every 1\u20132 weeks as needed. A rapid and dramatic clinical and laboratory response was achieved in all patients. Lymphocyte counts dropped markedly followed by shrinkage of lymph nodes and spleen and improvement of the anemia and thrombocytopenia. This could be maintained over 8 months (median) with additional cycles if necessary. Treatment was well tolerated in all cases. In conclusion, adding FFP to RTX may provide a useful therapeutic option in patients with advanced CLL resistant to treatment. Further studies are needed to confirm and study the efficacy of the FFP\/RTX combination in advanced CLL, establish the mechanisms, and possibly extend its use to other B\u2010cell\u2010dependent pathologies, such as treatment\u2010refractory autoimmune diseases.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2009.04803.x","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T22:02:36Z","timestamp":1251842556000},"page":"865-873","source":"Crossref","is-referenced-by-count":54,"title":["Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma"],"prefix":"10.1111","volume":"1173","author":[{"given":"Abraham","family":"Klepfish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugassy","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotsianidis","family":"Ioannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachmilewitz","family":"Eliezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schattner","family":"Ami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,9]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041720"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.273"},{"key":"e_1_2_9_4_2","volume-title":"Surveillance Epidemiology and End Results (SEER)","author":"Chronic lymphocytic leukemia"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404802"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.8.1105"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.2878.2878"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.10.005"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2153"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1326"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3383"},{"key":"e_1_2_9_12_2","first-page":"152","article-title":"Autoimmunity and autoimmune syndromes associated with and preceding the development of lymphoproliferative disorders","volume":"6","author":"Polliack A.","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000029993"},{"key":"e_1_2_9_14_2","first-page":"389","article-title":"Repressed classical complement pathway activities and clinical correlations in chronic lymphocytic leukemia","volume":"43","author":"Miszlai Z.","year":"1986","journal-title":"Acta Med. Hung."},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(89)90133-8"},{"key":"e_1_2_9_16_2","first-page":"489","article-title":"Depressed classical complement pathway activities in chronic lymphocytic leukemia","volume":"60","author":"Fust G.","year":"1985","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb03480.x"},{"key":"e_1_2_9_18_2","first-page":"1509","article-title":"The Complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives","volume":"10","author":"Schlesinger M.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0876"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.3280"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106846"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50025"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70106-7"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8513"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50025"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210365"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0066"},{"key":"e_1_2_9_29_2","article-title":"Use of rituximab in patients with systemic lupus erythematosus: An update","author":"Garc\u00eda\u2010Carrasco M.","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00063-005-1115-0"},{"key":"e_1_2_9_31_2","first-page":"328","article-title":"Ofatumumab (HuMax\u2010CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine\u2010refractory disease: results from the planned interim analysis of an international pivotal trial","volume":"112","author":"Osterborg A","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_32_2","article-title":"Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression\u2010free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL)","volume":"112","author":"Hallek M.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_33_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/BOR.0b013e3282f1330c","article-title":"Treatment of hepatitis C\u2010associated mixed cryoglobulinemia vasculitis","volume":"20","author":"Saadoun D.","year":"2008","journal-title":"Curr. Opin. Rheumatol."},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2008.02185.x"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2882"},{"key":"e_1_2_9_36_2","article-title":"Treatment of B\u2010cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single\u2010agent and combination therapy","author":"Faderl S.","year":"2008","journal-title":"Leukemia"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.05.014"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06974.x"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.12.011"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2009.04803.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2009.04803.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T07:41:16Z","timestamp":1695627676000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2009.04803.x"}},"subtitle":["Complement\/Rituximab Interactions &amp; Clinical Results in Refractory CLL"],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1749-6632.2009.04803.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04803.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}